The total number of records retrieved from this search are 47. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_10	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_11	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_12	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result38% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_13	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_14	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result95% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_15	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_16	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result77% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_17	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result72% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_18	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_718	Virus nameAvian influenza A virus	Virus strainH7N3 NS1-77	Virus genome typeRNA	Virus familyOrthomyxoviridae	Virus genome modificationMutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayImmunoassay detection	In-vitro virus concentration0.001 MOI	In-vitro result70% cancer cell death (calculated as relative to mock-infected)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-aplha	Clinical trialNA	PMID27417501
IDOV_722	Virus nameAvian influenza A virus	Virus strainH7N3	Virus genome typeRNA	Virus familyOrthomyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayImmunoassay detection	In-vitro virus concentration0.001 MOI	In-vitro result90% cancer cell death (calculated as relative to mock-infected)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-aplha	Clinical trialNA	PMID27417501
IDOV_2272	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2286	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2300	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2314	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result2% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2328	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2342	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result2% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2356	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result2% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2370	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result2% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2384	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2398	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2408	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic mice xenograft for MIA PaCa2 cell line	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor weight below 5 mg after 25 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_3409	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3410	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.25 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3411	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3412	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.75 MOI	In-vitro result28% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3413	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration1 MOI	In-vitro result25% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3426	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine 3 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result50% of tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3427	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (3 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3434	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (5 × 10⁻³ micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result50% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3435	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (5 × 10⁻³ micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3446	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result60% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3447	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.75 MOI	In-vitro result55% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3448	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration1 MOI	In-vitro result55% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3449	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3450	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.75 MOI	In-vitro result45% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3451	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_4296	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreas carcinoma	Cell lineMIAPaCa-2	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result49.1 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5345	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result78% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5346	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result78% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5347	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine 0.01 micromoar	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cells remain viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5348	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine 0.01 micromoar	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result50% cells remain viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5349	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine 0.05 micromoar	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result35% cells remain viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5350	Virus nameAdenovirus	Virus strainYDC002	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having insertion mutant for relaxin gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine 0.05 micromoar	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineMIAPaCa-2	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result30% cells remain viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID28315430
IDOV_5561	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineMIAPaCa-2	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultSignificant death of cancer cell line after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5566	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineMIAPaCa-2	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultSignificant death of cancer cell line after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5571	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationSindbis virus in combination with Reovirus	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineMIAPaCa-2	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultEnhancer cytolytic effect in combination after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2